LYPD3
LYPD3, also known as C4.4A, is a member of the LY6/PLAUR domain containing gene group and is found at the cell membrane. It supports cell migration and has been linked to urothelial cell-matrix interactions and tumour progression. Browse Assay Genie's current range of LYPD3 research reagents below, or read on for the biology behind the target.
LYPD3 (LY6/PLAUR domain containing 3) is a cell membrane protein annotated in UniProt as supporting cell migration. It may also be involved in urothelial cell-matrix interactions, and it may contribute to tumour progression. These annotations are cautious, and the detailed molecular mechanism is not defined in the source data.
The NCBI Gene summary adds that LYPD3 is predicted to enable laminin binding activity, which fits a role at the interface between the cell surface and the extracellular matrix. It is also described as involved in the negative regulation of smooth muscle cell apoptotic process, and it is located in the plasma membrane. The human protein is encoded by the LYPD3 gene, and mouse and rat each carry an orthologue named Lypd3.
The protein name is Ly6/PLAUR domain-containing protein 3, and HGNC places it in the LY6/PLAUR domain containing gene group. It is also known by the alias C4.4A. Researchers studying cell migration, matrix adhesion, urothelial biology and tumour progression may therefore use LYPD3 as a target of interest, whether they are measuring the LYPD3 protein or investigating the LYPD3 gene.
LYPD3 is annotated as supporting cell migration, making it a relevant target for work on how cells move.
LYPD3 may take part in urothelial cell-matrix interactions and is predicted to bind laminin, an extracellular matrix component.
UniProt notes that LYPD3 may be involved in tumour progression, which motivates its study in cancer biology.
LYPD3 is described as involved in negative regulation of the smooth muscle cell apoptotic process.
UniProt annotates LYPD3 as supporting cell migration. It may also be involved in urothelial cell-matrix interactions and in tumour progression. NCBI Gene adds that it is predicted to enable laminin binding and is involved in negative regulation of smooth muscle cell apoptosis.
Yes. C4.4A is an alias for LYPD3. The approved HGNC name is LY6/PLAUR domain containing 3, and UniProt lists the protein as Ly6/PLAUR domain-containing protein 3. Both names may appear in the literature, so searching for either is sensible.
Yes. Orthologues named Lypd3 are listed for both mouse and rat, so the gene can be studied in common rodent models. Cross-reactivity differs between reagents, so check the datasheet of any product for its validated reactivity.
Other LY6/PLAUR domain containing proteins, cell migration regulators and extracellular matrix interaction targets.
Gene and protein annotations from HGNC, NCBI Gene and UniProt O95274; product specifications from Assay Genie datasheets.